文献速递淋巴瘤

剂量调整EPOCH-R方案治疗儿童青少年原发纵隔大B细胞淋巴瘤的多中心II期试验

Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial.
PubMed 文献 · J Clin Oncol · 2021-09-27

这项国际单臂II期试验评估了DA-EPOCH-R方案在46例18岁以下原发纵隔大B细胞淋巴瘤患者中的疗效,患者接受6个疗程治疗。结论认为该方案未能改善无事件生存,需进一步研究最佳治疗。

要点

  • 总生存率为84.8%,14例事件中包括8例复发或进展(含3例中枢神经系统实质复发)。
  • 65%患者发生≥3级非血液学或≥2级心脏不良事件,需关注毒性管理。

核心结论

  • 在儿童青少年原发纵隔大B细胞淋巴瘤中,DA-EPOCH-R方案的EFS未优于历史对照。
  • 需进一步研究确定该人群的最佳治疗策略。

研究设计与样本

  • 国际单臂II期试验,纳入46例年龄小于18岁的原发纵隔大B细胞淋巴瘤患者。
  • 患者接受6个疗程DA-EPOCH-R方案治疗,主要终点为无事件生存期。

主要发现

  • 中位年龄15.4岁(四分位距14-16岁),中位随访59.0个月(四分位距52.6-69.2个月)。
  • 共观察到14例事件:8例复发或进展(含3例中枢神经系统实质复发)、4例残留淋巴瘤、2例第二恶性肿瘤。
  • 总生存率为84.8%(95% CI 71.8-92.4),7例死亡(6例疾病相关,1例第二恶性肿瘤)。

关键数值与推荐

  • 4年无事件生存率69.6%(95% CI 55.2-80.9)。
  • 总生存率84.8%(95% CI 71.8-92.4)。

临床怎么用

  • DA-EPOCH-R方案在儿童青少年原发纵隔大B细胞淋巴瘤中未显示优于历史对照的EFS。
  • 治疗中需密切监测非血液学和心脏毒性,65%患者发生≥3级非血液学或≥2级心脏不良事件。

局限性

  • 单臂II期试验,无随机对照,样本量46例。
  • 与历史对照比较可能存在混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab (DA-EPOCH-R) regimen has been shown to deliver excellent survival for adults with primary mediastinal large B-cell lymphoma (PMLBL) without the use of radiotherapy. No international prospective evaluation of this regimen has previously been reported in children and adolescents. PATIENTS AND METHODS: We conducted an international single-arm phase II trial involving patients younger than age 18 years with PMLBL who were to receive six courses of DA-EPOCH-R. The primary end point was event-free survival (EFS). Overall survival and toxicity were also assessed. This trial was registered (ClinicalTrials.gov identifier: NCT01516567). RESULTS: Analyses were based on 46 patients. The median age was 15.4 years (interquartile range: 14-16 years). The median follow-up was 59.0 months (interquartile range: 52.6-69.2 months). Fourteen events were observed (eight relapses or progressions (including three parenchymal CNS relapses), four residual lymphoma, and two second malignancies). The 4-year EFS was 69.6% (95% CI, 55.2 to 80.9), which did not differ from the rate observed historically (P = .59). Seven deaths occurred (six disease-related and one second malignancy). The overall survival was 84.8% (95% CI, 71.8 to 92.4). Twenty-two patients (48%) reached dose levels ≥ 4. Nonhematologic adverse events grade ≥ 3 or cardiac adverse events grade ≥ 2 occurred in 47 of 276 (17%) courses and 30 of 46 patients (65%). CONCLUSION: DA-EPOCH-R did not improve the EFS compared with a historical control in this first prospective multisite international study of children and adolescents with PMLBL. Further studies are required to determine the optimum therapy for children and adolescents with this lymphoma.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Burke GAA, Minard-Colin V, Aupérin A, et al. Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. J Clin Oncol. 2021. PMID: 34570655. doi:10.1200/JCO.21.00920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。